Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials

References

• Kuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K, Komatsu I, Yamazoe M, Takahashi O, Hisatome I. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37(8):785–89. doi:https://doi.org/10.1038/hr.2014.75. Cited in: PMID: 24671018.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–06. doi:https://doi.org/10.1161/hy1101.092839. Cited in: PMID: 11711505.
   PubMed Web of Science ®Google Scholar
• Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study. Clin Drug Investig. 2015;35(12):823–31. doi:https://doi.org/10.1007/s40261-015-0349-8. Cited in: PMID: 26482071.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Lozada LGS, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018;71(6):851–65. doi:https://doi.org/10.1053/j.ajkd.2017.12.009. Cited in: PMID: 29496260.
   PubMed Web of Science ®Google Scholar
• Sakaki M, Tsuchihashi T. Current status of uric acid level in treated hypertensive patients. Gout Nucleic Acid Metabolism. 2013;37(2):103–09. doi:https://doi.org/10.6032/gnam.37.103.
   Google Scholar
• Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2019). Hypertens Res. 2019;42(9):1235–481. doi:https://doi.org/10.1038/s41440-019-0284-9. Cited in: PMID: 31375757.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371(1):162–70. doi:https://doi.org/10.1124/jpet.119.259341. Cited in: PMID: 31371478.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Takahashi T, Taniguchi T, Hosoya T. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021;1–10. doi:https://doi.org/10.1080/14656566.2021.1918102. Cited in: PMID: 33926357.
   Google Scholar
• Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020;24(Suppl 1):S44–S52. doi:https://doi.org/10.1007/s10157-019-01802-w. Cited in: PMID: 31754882.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol. 2020;24(Suppl 1):S53–S61. doi:https://doi.org/10.1007/s10157-019-01818-2. Cited in: PMID: 31792640.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol. 2020;24(Suppl 1):S62–S70. doi:https://doi.org/10.1007/s10157-020-01849-0. Cited in: PMID: 31980978.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24(Suppl 1):S71–S79. doi:https://doi.org/10.1007/s10157-020-01851-6. Cited in: PMID: 31970593.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24(Suppl 1):S80–S91. doi:https://doi.org/10.1007/s10157-019-01831-5. Cited in: PMID: 31875931.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. Japanese society of gout and nucleic acid metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–29. doi:https://doi.org/10.1080/15257770.2011.596496. Cited in: PMID: 22132951.
   PubMed Web of Science ®Google Scholar
• Hisatome I, Ichida K, Mineo I, Ohtahara A, Ogino K, Kuwabara M, Ishizaka N, Uchida S, Kurajoh M, Kohagura K, et al. Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition. Gout and Uric Nucleic Acids. 2020;44(Suppl).
   Google Scholar
• Goicoechea M, Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93. doi:https://doi.org/10.2215/CJN.01580210. Cited in: PMID: 20538833.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Maruyama Y, Nishio S, Takahashi Y, Kidoguchi S, Kobayashi C, Takahashi D, Sugano N, Hosoya T, Yokoo T. Serum uric acid and the incidence of CKD and hypertension. Clin Exp Nephrol. 2015;19(6):1127–34. doi:https://doi.org/10.1007/s10157-015-1120-4. Cited in: PMID: 25967597.
   PubMed Web of Science ®Google Scholar
• Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447–52. doi:https://doi.org/10.1038/nature742. Cited in: PMID: 12024214.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovasc Diabetol. 2013;12:159. doi:https://doi.org/10.1186/1475-2840-12-159. Cited in: PMID: 24180232.
   PubMed Web of Science ®Google Scholar
• Salem CB, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2017;56(5):679–88. doi:https://doi.org/10.1093/rheumatology/kew293. Cited in: PMID: 27498351.
   PubMed Web of Science ®Google Scholar
• Okusa MD, Persson AE, Wright FS. Chlorothiazide effect on feedback-mediated control of glomerular filtration rate. Am J Physiol. 1989;257(1 Pt 2):F137–F144. doi:https://doi.org/10.1152/ajprenal.1989.257.1.F137. Cited in: PMID: 2750918.
   PubMedGoogle Scholar
• Jutabha P, Anzai N, Kitamura K, Taniguchi A, Kaneko S, Yan K, Yamada H, Shimada H, Kimura T, Katada T, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010;285(45):35123–32. doi:https://doi.org/10.1074/jbc.M110.121301. Cited in: PMID: 20810651.
   PubMed Web of Science ®Google Scholar
• Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103–08. doi:https://doi.org/10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C. Cited in: PMID: 10643705.
   PubMed Web of Science ®Google Scholar
• Ohta Y, Ishizuka A, Arima H, Hayashi S, Iwashima Y, Kishida M, Yoshihara F, Nakamura S, Kawano Y. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. Hypertens Res. 2017;40(3):259–63. doi:https://doi.org/10.1038/hr.2016.139. Cited in: PMID: 27760998.
   PubMed Web of Science ®Google Scholar
• Gunawardhana L, McLean L, Punzi HA, Hunt B, Palmer RN, Whelton A, Feig DI. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study. J Am Heart Assoc. 2017;6(11):e006683. doi:https://doi.org/10.1161/JAHA.117.006683. Cited in: PMID: 29102979.
   PubMed Web of Science ®Google Scholar